Progressive Pulmonary Fibrosis (PPF) represents a critical unmet need, driven by complex inflammatory and fibrotic pathways that continue to challenge existing therapies. Our work focuses on advancing a targeted biologic approach designed to intervene earlier in disease progression and improve meaningful clinical outcomes.